The tumour marker now known as prostate-specific antigen (PSA) was identified in 1970 5, but it was not until the late 1980s that the first definitive study investigating its clinical utility in prostate cancer was published 6 and another decade later until establishment of the 1st International Standard for PSA 7. Here, KLK3 is linked to prostate cancer.